Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Dermatology/Plastic Surgery | Oncology
Melanoma
Identification of Genes and Pathways in Tumorigenesis and Progression of Malignant Melanoma
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
DERMA Clinical Research Study in Melanoma MAGE-A3 Immunotherapy
Dinaciclib in Treating Patients With Stage IV Melanoma SWOG S0826
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A double-blind randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma.
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
A Phase III Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Melanoma
A Phase III Study to Test the Benefit of a New Kind of Anti-Cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor.
A randomized, double-blind, placebo-controll, phase 2 study evaluating the efficacy fo ABT-888 in combination with temozolomide versus temozolomide alone in subjects with metastatic melanoma.
A Randon - Assignment Study of Hepatic Arterial Infusion of Melphalan with Venous Filtration via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver.
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Adjuvant Immunotherapy with Anti-CTLA-4 Monocional Anitbody (Ipilimumab) versus Placebo after Complete Resection of High-Risk Stage III Melanoma: A Randomized, Double-Blind Phase 3 Trial of te EORTC Melanoma Group.
Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Trial of Dacarbazine With or Without Genasense in Advanced Melanoma (AGENDA)
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
Participants With Melanoma sought For research Study
A Phase II Study Using a Regimen of Chemotherapy (cyclophosphamide and fludarabine), Followed by Short-term Anti-tumor Autologous Lymphocytes (Y-TIL) and Aldesleukin Therapy for Subjects with Metastatic Melanoma
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line
Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
